These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31209163)

  • 1. Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals.
    Telikepalli S; Gonzalez K; Dragulin-Otto S; Ripple D; Carrier M; Khan M
    PDA J Pharm Sci Technol; 2019; 73(5):418-432. PubMed ID: 31209163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Interlaboratory Study to Identify Potential Visible Protein-Like Particle Standards.
    Telikepalli SN; Carrier MJ; Ripple DC; Barnett G; Bhirde A; Bolton D; Bou-Assaf GM; Ferrari E; Leigh S; Levitskaya-Seaman S; Menzen T; Nikels F; Riley A; Saggu M; Sahni N; Vernooij E; Wuchner K
    AAPS PharmSciTech; 2022 Dec; 24(1):18. PubMed ID: 36526853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introducing the Alba
    Chillon A; Pace A; Zuccato D
    PDA J Pharm Sci Technol; 2018; 72(4):382-392. PubMed ID: 29853611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening techniques for monitoring the sub-visible particle formation of free fatty acids in biopharmaceuticals.
    Chen W; Klemm D; Gregoritza K; Satya Krishna Kishore R; Olaf Stracke J; Wurth C; Pinto C; Sancho Oltra N
    Eur J Pharm Biopharm; 2023 Sep; 190():242-247. PubMed ID: 37524212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations.
    Akhunzada ZS; Hubert M; Sahin E; Pratt J
    Curr Pharm Biotechnol; 2019; 20(3):232-244. PubMed ID: 30767738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Diameter Accuracy for Dynamic Imaging Microscopy for Different Particle Types.
    Cavicchi RE; Ripple DC;
    J Pharm Sci; 2020 Jan; 109(1):488-495. PubMed ID: 31628920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphologically-Directed Raman Spectroscopy as an Analytical Method for Subvisible Particle Characterization in Therapeutic Protein Product Quality.
    Kim M; Ma Y; Srinivasan C; O'Connor T; Telikepalli SN; Ripple DC; Lute S; Bhirde A
    Sci Rep; 2023 Nov; 13(1):20473. PubMed ID: 37993487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case for Expanding Thermochromic Vial Monitor Technology to Insulin and Other Biologics.
    Virmani A; Avni TCA
    Indian Pediatr; 2020 Jan; 57(1):17-19. PubMed ID: 31937691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Considerations for Detection and Characterization of Sub-Micron Particles in Protein Solutions by Nanoparticle Tracking Analysis.
    Gruia F; Parupudi A; Polozova A
    PDA J Pharm Sci Technol; 2015; 69(3):427-39. PubMed ID: 26048748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Protein-like Model Particles Fabricated by Micro 3D Printing to Established Standard Particles.
    Amara I; Germershaus O; Lentes C; Sass S; Youmto SM; Stracke JO; Clemens-Hemmelmann M; Assfalg A
    J Pharm Sci; 2024 Apr; ():. PubMed ID: 38615817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sub-visible particle quantitation in protein therapeutics.
    Cao S; Jiao N; Jiang Y; Mire-Sluis A; Narhi LO
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):73-9. PubMed ID: 20144454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Particles in therapeutic protein formulations, Part 1: overview of analytical methods.
    Zölls S; Tantipolphan R; Wiggenhorn M; Winter G; Jiskoot W; Friess W; Hawe A
    J Pharm Sci; 2012 Mar; 101(3):914-35. PubMed ID: 22161573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
    Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
    J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis.
    Strehl R; Rombach-Riegraf V; Diez M; Egodage K; Bluemel M; Jeschke M; Koulov AV
    Pharm Res; 2012 Feb; 29(2):594-602. PubMed ID: 21948455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical review of analytical methods for subvisible and visible particles.
    Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
    Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of surfaces and leachables on the stability of biopharmaceuticals.
    Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN
    J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility.
    Mazaheri M; Saggu M; Wuchner K; Koulov AV; Nikels F; Chalus P; Das TK; Cash PW; Finkler C; Levitskaya-Seaman SV; Case J; Parsons J; Gonzalez K
    J Pharm Sci; 2024 Mar; 113(3):616-624. PubMed ID: 37802369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.